IL6 and hepatocellular carcinoma: In consistence, a study obtaining peripheral immune cells and cytokine profiles of patients with HCC reported that the administration of lenvatinib reduced the numbers of T helper cells and Treg cells, significantly increased the numbers of cytotoxic T cells, increased IL-2, IFN-γ, and IL-5 levels, and decreased IL-6, IL-10, TNF-α, and TNF-β levels, suggesting that further investigations into the immunomodulatory effect of lenvatinib on TME are needed [110].